Cancer responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)

The vast majority of our knowledge regarding cancer radiobiology and the activation of radio-resistance mechanisms emerged from studies using external beam radiation therapy (EBRT). Yet, less is known about the cancer response to internal targeted radionuclide therapy (TRT). Our comparative proteomics and phosphoproteomics study analyzed response to TRT with lutetium-177 labeled minigastrin analogue [177Lu]Lu-PP-F11N (β- emitter) in comparison to EBRT (ɣ-rays) in CCKBR-positive cancer cells.

目前学界有关癌症放射生物学及辐射抗性机制激活的认知，绝大多数源自外照射放疗（external beam radiation therapy, EBRT）相关研究。然而，人们对于癌症对内靶向放射性核素治疗（internal targeted radionuclide therapy, TRT）的应答反应却知之甚少。本研究采用比较蛋白质组学与磷酸化蛋白质组学手段，针对胆囊收缩素B受体（CCKBR）阳性癌细胞，分析其对镥-177标记的小胃泌素类似物[177Lu]Lu-PP-F11N（β辐射体）介导的内靶向放射性核素治疗的应答情况，并与γ射线外照射放疗（EBRT）进行对照分析。